CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.)

348 articles with CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.)

• Casi Pharmaceuticals Announces Reverse Stock Split - May 26, 2022

  5/26/2022

  CASI Pharmaceuticals, Inc. announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-10 reverse stock split that will become effective at 5:00 p.m., Eastern Time, on June 1, 2022.

• CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD

  5/24/2022

  CASI Pharmaceuticals, Inc. today announced the signing of a Sublicense Agreement with Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd., ("TIANSHI") a clinical stage pharmaceutical company organized and existing under the laws of the People's Republic of China ("PRC").

• CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

  5/12/2022

  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2022.

• CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

  5/2/2022

  CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the first quarter of 2022, at 8:00 a.m. EST on Thursday , May 12, 2022.

• CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE

  3/28/2022

  CASI Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2021, and provided an update on key highlights for 2022. 

• CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022

  3/23/2022

  CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the fourth quarter and for the year ended December 31st, 2021, at 8:00 a.m. EDT on Monday, March 28th, 2022.

• CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA

  3/4/2022

  CASI Pharmaceuticals, Inc. announced today, that the Company has entered into a renewal exclusive distribution agreement, whereby under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.

• CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES

  2/16/2022

  CASI Pharmaceuticals, Inc. today announced preliminary and unaudited revenues for the fourth quarter and full-year 2021 and provided an update on key highlights for 2022.

• CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA

  1/20/2022

  CASI Pharmaceuticals, Inc. announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner BioInvent International AB, for BI-1206, an investigational anti-FcyRllB antibody, for the treatment of follicular lymphoma (FL), the most common form of slow-growing Non-Hodgkin lymphoma (NHL).

• CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA

  1/18/2022

  CASI Pharmaceuticals, Inc. announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner Juventas Cell Therapy LTD.

• CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE

  1/3/2022

  CASI Pharmaceuticals, Inc. today announced that on December 30, 2021 , CASI received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market.

• CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM

  12/17/2021

  CASI Pharmaceuticals, Inc. today announced that its board of directors approved a stock repurchase program for the repurchase of up to USD 10 million of the Company's common stock.

• BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

  12/10/2021

  BioInvent International AB today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application (CTA) submitted by BioInvent's licensee in China, CASI Pharmaceuticals (CASI).

• CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA

  12/10/2021

  CASI Pharmaceuticals, Inc. today announces that the China National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) for BI-1206.

• CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference

  11/15/2021

  CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that Mr. Larry Zhang, President of CASI Pharmaceuticals, will be presenting at the Jefferies London Healthcare Conference.

• CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results

  11/12/2021

  CASI Pharmaceuticals, Inc., is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported financial results for the third quarter of 2021.

• CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021

  11/5/2021

  CASI Pharmaceuticals, Inc. announced additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206.

• CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021

  11/2/2021

  CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the third quarter highlights at 8:00 a.m. EDT on Friday , November 12th , 2021.

• CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

  10/25/2021

  CASI Pharmaceuticals, Inc. today reported that Juventas Cell Therapy Ltd. ("Juventas") has completed  a Series C financing round through which it raised more than RMB410 million (approximately $63 million (USD)). 

• CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/20/2021

  CASI Pharmaceuticals, Inc. announced that Dr. Alexander Zukiwski , Chief Medical Officer of CASI Pharmaceuticals, will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit